Value Picks – Long term Investments

Wealth creation with Long term investment 5-10-15-20 years

Subscribe Paid investment Newsletter
Join Telegram Channel
Paid Portfolio Plans

Tag: top performing stocks

  • ITC 2025-2045 Growth Plan: Share Price to Soar 6x

    ITC Ltd – Complete Q3 FY2025 Performance Analysis & Future Growth Outlook

    ITC Ltd – Q3 FY2025 Performance Analysis

    Comprehensive Financial Results & Strategic Outlook

    Executive Summary

    ITC delivered a resilient Q3 performance amid a subdued demand environment and rising input costs. The diversified business—spanning FMCG, agri, and paperboards/packaging—continues to underpin a robust operating model. With a premium brand portfolio, strategic capital investments, and strong sustainability credentials, ITC is well positioned for medium‐ to long‐term growth despite inherent sector risks.

    Q3 FY2025 Results Overview

    Gross Revenue

    ₹18,953 Cr

    Up 8.4% YoY

    Net Revenue

    ₹17,726 Cr

    8.6% Growth

    EBITDA

    ₹6,197 Cr

    Up 2.9% YoY

    PBT

    ₹7,363 Cr

    Up 9.5% YoY

    Segmental Performance

    FMCG Cigarettes

    Revenue up ~8% YoY, driven by volume growth and premium innovation amid cost pressures in leaf tobacco.

    FMCG Others

    4% YoY growth (5.2% ex-Notebooks) through brands like Aashirvaad, Sunfeast, and Classmate, despite challenging backdrop in notebooks segment.

    Agri Business

    Revenue up 9.7% YoY, with robust performance in value-added exports (coffee, spices) and leaf tobacco.

    Paperboards & Packaging

    3.1% YoY growth through export-led initiatives and cost management, despite soft domestic demand and high Chinese imports.

    Dividend & Capital Structure

    Interim Dividend

    ₹6.50

    Per Share

    Market Cap

    ₹5,03,627 Cr

    Net Debt

    ₹304 Cr

    Reserves

    ₹74,015 Cr

    Future Growth Plans & Expansion Strategy

    Product & Brand Expansion

    • Continued innovation across FMCG portfolios with expanded value-added variants for Aashirvaad
    • Premium positioning for Sunfeast and Classmate
    • New product launches in personal care and packaged foods
    • ITC Infotech’s digital solutions expansion

    Planned Capacity Enhancements

    • Third Ancillary Manufacturing cum Logistics Facility (AMLF)
    • New premium moulded fibre products plant in Madhya Pradesh
    • Hotels business demerger (ITC Hotels Ltd)

    Sustainability & Digital Initiatives

    • Maintaining water positive and carbon positive status
    • ESG initiatives for reputation enhancement and cost optimization
    • ITC Infotech investments for digital capabilities

    Future Financial Projections

    Timeline Projected Share Price Growth Drivers
    5 Years (2030) ₹650 Diversified revenue base, strong brand equity, ongoing cost efficiencies
    10 Years (2035) ₹1,040 Margin expansion, robust cash flows, market share growth
    15 Years (2040) ₹1,685 Compounded reinvestment, sustainable growth initiatives
    20 Years (2045) ₹2,710 Strategic capital expenditure, competitive advantages

    Capital Expenditure & Strategic Rationale

    Capex Focus

    Investments in modern manufacturing facilities aimed at reducing total delivered cost and improving market responsiveness. Capital allocation prioritizes digital transformation and distribution channel enhancement.

    Strategic Rationale

    Focus on efficiency gains and market share expansion to maintain healthy margins (current OPM ~35.0%) and generate robust free cash flows for future dividend growth and strategic investments.

    Competitive Landscape & Risks

    Strengths

    • Diversified business model reducing segment dependency
    • Strong brand recognition and extensive distribution network
    • Best-in-class sustainability practices

    Challenges & Risks

    • Input cost volatility (edible oil, wheat, wood)
    • Global supply chain disruptions
    • Regulatory risks in tobacco segment
    • Increased competition from local players
    • Geopolitical uncertainties and forex fluctuations

    Valuation & Investment Thesis

    Current Price

    ₹403

    P/E Ratio

    25.4

    Book Value

    ₹60.2

    Dividend Yield

    3.42%

    ROCE

    37.5%

    ROE

    28.4%

    Investment Thesis

    • Defensive Yet Growth-Oriented: ITC’s diversified operations, strong brands, and operational efficiency make it a defensive play with attractive upside in a growth scenario.
    • Sustainable Expansion: Focused investments in capacity, product innovation, and digital transformation are expected to drive future profitability and shareholder returns.
    • Valuation Upside: DCF and relative valuation models suggest a near-term target price in the ₹420–450 range, with long-term upside driven by compounded earnings growth.
    • Strong Balance Sheet: Low net debt, high reserves, and robust returns (ROCE 37.5%, ROE 28.4%) indicate reasonable valuation given scale and resilience.

    Key Performance Indicators

    • Strong market position across diverse business segments
    • Consistent dividend payout history
    • Robust cash flow generation capabilities
    • Proven track record in sustainability initiatives
    • Strategic investments in future growth areas

    Return Estimates & Growth Assumptions

    Based on a conservative earnings growth rate of approximately 10% p.a., supported by:

    • Diversified revenue streams providing stability
    • Strong brand equity driving premium pricing
    • Operational efficiencies from strategic investments
    • Market share gains in key segments
    • Sustainable competitive advantages

    Disclaimer

    This report is provided for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research or consult a professional financial advisor before making any investment decisions. The projections and estimates contained herein are based on various assumptions and may not materialize as expected. Past performance is not indicative of future returns.

    x

  • Satin Creditcare: 5-20-Year Growth & ROI Projections Unveiled

    Satin Creditcare Network Ltd – Complete Q3 FY2025 Analysis

    Satin Creditcare Network Ltd

    Comprehensive Q3 FY2025 Equity Research Report

    Executive Summary

    Market Cap

    ₹1,605 Cr

    Stock Price

    ₹145

    P/E Ratio

    5.48

    Book Value

    ₹230

    Satin Creditcare Network Ltd—a leading rural NBFC with over 34 years of legacy—delivered Q3 FY2025 results that underscore its resilient operating model, strategic expansion, and technology–driven efficiency. With attractive valuation multiples, the company appears undervalued relative to its strong operational fundamentals and growth potential. However, high leverage (debt ~₹8,388 Cr) and margin pressures require careful monitoring.

    Q3 FY2025 Results Overview

    AUM Growth

    Consolidated AUM climbed to ₹12,128 Cr in Q3 FY2025—a 10% YoY increase—with SCNL’s AUM rising from ~₹9,811 Cr to ~₹10,778 Cr, reflecting strong disbursement performance and branch expansion (up 11% QoQ).

    Profitability & Asset Quality

    Q3 PAT

    ₹31 Cr

    Collection Efficiency

    99.8%

    Credit Costs

    <5.0%

    Operational Efficiency

    Improved cost ratios and robust underwriting processes have helped maintain competitive net interest margins despite sector headwinds.

    Future Growth Plans & Expansion

    Geographical & Product Diversification

    The company continues expanding its branch network and deepening market penetration across 29 states. Its diversified product suite now spans microfinance (MFI), housing finance (SHFL), MSME lending (SFL), and a technology platform via Satin Technologies.

    Technology & Process Initiatives

    Heavy capital allocation into IT infrastructure—such as digital onboarding, real-time analytics, and AI/ML underwriting enhancements—is designed to reduce turnaround times, improve risk management, and drive operational efficiency.

    Future Financial Projections

    Timeline Growth Factor Expected Returns Key Assumptions
    5 Years 1.6× 60-70% cumulative Margin improvements, balance sheet deleveraging
    10 Years 2.6× 2-3× current price Sustained growth trajectory
    15 Years 4.2× Substantial wealth creation Successful capital expenditure
    20 Years 6.7× Significant capital appreciation Effective risk management

    Product Portfolio & Capital Expenditure Strategy

    Product Offerings

    • MFI Loans: Catering to low-income rural households with ticket sizes up to ₹100,000
    • Housing Finance (SHFL): Targeting middle to low-income segments with larger loan sizes and longer tenures
    • MSME Lending (SFL): Focus on secured, small–ticket business loans (<₹2 Lacs) with significant growth potential
    • Technology Initiatives: Satin Technologies leverages in–house IT solutions

    Capital Expenditure Strategy

    Investments are directed towards:

    • Expanding branch networks
    • Digital platforms development
    • Risk management systems enhancement

    Competitive Landscape & Inherent Risks

    Competitive Position

    Satin stands out due to its diversified rural footprint, strong technological integration, and a long history of profitable operations. Its product diversification and efficient ALM offer a competitive edge over traditional NBFC-MFIs and local banks.

    Key Risks

    High Leverage Asset Quality Risk Regulatory Risk Margin Pressure Competitive Disruption

    Valuation Estimate & Investment Thesis

    Valuation Metrics

  • Tata Motors 2025-2040 Roadmap: 22% EV Growth CAGR, ₹4.4L Cr Revenue & Next-Gen Mobility Strategy

    Tata Motors Q3 2025 Results: Strategic Growth & EV Dominance | Automotive Investment Analysis

    Tata Motors Q3 2025 Financial Report

    Comprehensive Analysis & Future Growth Projections

    Q3 2025 Financial Highlights

    ₹4,43,059 Cr

    Quarterly Revenue

    ₹31,834 Cr

    Net Profit (+128% YoY)

    14.2%

    EBITDA Margin

    Electric Vehicle Milestones

    Q3 2025 EV Sales Growth

    +67% YoY increase in electric vehicle sales

    New Battery Tech Partnership

    Announced solid-state battery collaboration with leading tech firms

    Risk Assessment

    Debt Level ₹1,06,549 Cr
    Supply Chain Monitoring
    EV Market Competition

    2025-2040 Growth Projections

    • EV Division CAGR 22% (2025-2030)
    • JLR Global Expansion Plan
    • Autonomous Tech Roadmap

  • Glenmark Pharmaceuticals Ltd. – Equity Research Report Q3 FY2025

    Snapshot


    • Market Cap: ₹38,069 Cr.  |  Current Price: ₹1,349
    • 52-Week Range: ₹1,831 / ₹883
    • Book Value: ₹299  |  Dividend Yield: 0.19%
    • ROCE: 12.3%  |  ROE: -50.9%
    • Debt/Reserves: ₹1,711 Cr. / ₹8,417 Cr.
    • Sales: ₹13,128 Cr.  |  OPM: 17.5%
    • Promoter Holding: 46.6%

    1. Executive Summary

    Glenmark Pharmaceuticals has delivered robust top-line growth in Q3 FY2025 with consolidated revenue climbing by 35.1% YoY to ₹33,876 Mn. Despite margin pressures and an underperforming profit figure compared to prior quarters, the company is aggressively investing in portfolio expansion, R&D, and regulatory filings. Its focus on respiratory, dermatology, and injectable segments—combined with strategic global partnerships—positions Glenmark well for medium-term growth, even as regulatory and currency headwinds persist.

    2. Q3 FY2025 Financial Performance

    Key Financials:

    • Revenue & Margins:
      • Consolidated revenue: ₹33,876 Mn (+35.1% YoY)
      • Gross margin improved from 58.8% to 68.0%, indicating operational efficiencies and a better product mix.
    • Profitability Metrics:
      • EBITDA of ₹6,002 Mn (margin 17.7%) versus a previous loss, reflecting a turnaround in core operations.
      • PAT reached ₹3,480 Mn (margin 10.3%), recovering from negative performance last year.
    • Segment Insights:
      • India: Rs. 10,637 Mn with an explosive YoY growth of 300%, reinforcing its strong domestic position.
      • North America & Europe: Stable revenues with Europe growing 14.8% YoY, driven by the respiratory portfolio.
      • ROW: Modest growth (3.0% YoY) impacted by adverse currency movements.

    Supplementary Data:

    The company’s R&D expenditure stands at Rs. 2,249 Mn (6.6% of revenue), underlining its commitment to innovation.

    3. Strategic Initiatives & Future Growth

    Product Pipeline & Market Expansion

    • Dermatology & Respiratory:
      • MHRA approval for WINLEVI® in the UK sets the stage for an expanded dermatology portfolio.
      • RYALTRIS® is performing strongly across key European markets and is poised for launch in an additional 12–15 countries.
    • Injectables & Respiratory Innovations:
      • Recent launches of Travoprost Ophthalmic and Lacosamide Oral Solution are expected to generate incremental revenue in FY26.
      • Plans to file additional ANDA applications and further pipeline respiratory products indicate proactive regulatory positioning.

    R&D & Clinical Advancements

    • ICHNOS Platform:
      • ISB 2001 TREAT™, a trispecific antibody targeting multiple myeloma, has shown an encouraging 83% overall response rate in Phase 1, with further data expected at upcoming conferences.
    • Partnered Innovations:
      • Licensing deals with Pfizer, BeiGene, and strategic alliances with global partners such as Hikma and Menarini enhance market access and mitigate development risk.

    Capital Expenditure & Investment Rationale

    • CapEx Focus:
      • Investments are being channeled into enhancing manufacturing capacity for injectables and meeting global regulatory standards (e.g., USFDA filings).
    • Strategic Rationale:
      • CapEx initiatives aim to diversify revenue streams and create sustainable competitive advantages in high-growth therapeutic segments.

    4. Valuation & Investment Thesis

    Valuation Metrics:

    • Relative Valuation:
      • With industry peers trading at a P/E range of 20-25x, Glenmark’s growth trajectory and product diversification justify a premium valuation outlook once earnings normalize.
    • EV/EBITDA Approach:
      • Based on projected EBITDA improvements, a fair valuation range of ₹1,450–₹1,600 per share is estimated, reflecting expected margin stabilization and revenue growth post FY26.

    Investment Thesis:

    • Growth Catalyst:
      • Strategic portfolio expansions in respiratory and injectables, backed by regulatory approvals and global market penetration, are set to drive mid-term revenue growth.
    • Risk-Reward Balance:
      • While short-term volatility is possible due to regulatory risks and currency fluctuations, the company’s robust pipeline and strategic partnerships underpin a compelling long-term upside.
    • Buy Recommendation:
      • For investors with a medium- to long-term horizon, Glenmark represents an attractive opportunity to gain exposure to a well-diversified pharmaceutical player with a strong growth engine.

    5. Competitive Landscape & Risk Assessment

    Competitive Advantages:

    • Global Footprint:
      • Deep penetration in emerging and developed markets through strategic alliances.
    • Innovation & Differentiation:
      • A diversified product portfolio with strong brands in respiratory, dermatology, and oncology, coupled with a robust R&D pipeline.
    • Operational Efficiency:
      • Improved margins and cost control demonstrated by the turnaround in EBITDA performance.

    Risks & Mitigation:

    • Regulatory Hurdles:
      • Potential delays in USFDA approvals could impede product rollouts; diversified pipeline and global partnerships provide a buffer.
    • Currency Volatility:
      • Adverse forex movements have already impacted ROW revenue; hedging strategies and geographic diversification are key mitigants.
    • Competitive Pressure:
      • Intense competition in the generics space could squeeze margins; innovation and new product launches are essential to maintain market share.

    6. Conclusion & Disclaimer

    Glenmark Pharmaceuticals Ltd. has positioned itself strongly with a clear strategic focus on high-growth segments and global market expansion. With solid Q3 performance, an ambitious pipeline, and proactive investments in R&D and manufacturing, the company offers significant upside potential for long-term investors—despite near-term risks related to regulatory approvals and currency fluctuations.

    Disclaimer: This report is provided for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with a qualified financial advisor before making any investment decisions.

  • Amara Raja: ₹9,500 Cr EV Battery Push, 16 GWh Plant by 2030 | Q3 Up 11.4%

    Amara Raja Energy & Mobility Ltd – Q3 FY2025 Comprehensive Analysis

    Amara Raja Energy & Mobility Ltd

    Q3 FY2025 Stock Research Report

    NSE: ARE&M BSE: 500008 Industry: Energy Storage | EV Batteries | Lead-Acid Batteries

    Key Market Metrics

    Market Cap

    ₹19,568 Cr.

    Current Price

    ₹1,069

    52-Week Range

    ₹738 – ₹1,776

    P/E Ratio

    20.6

    Book Value

    ₹395

    Dividend Yield

    0.93%

    ROCE

    18.7%

    ROE

    14.0%

    Q3 FY2025 Financial Performance

    Revenue

    ₹3,272 Cr.

    +7.5% YoY

    EBITDA

    ₹460 Cr.

    +8.2% YoY

    Net Profit

    ₹298 Cr.

    +11.4% YoY

    EPS

    ₹16.3

    vs ₹14.6 Q3 FY24

    Key Takeaways

    • Revenue Growth driven by demand for lead-acid batteries in automotive, UPS, and industrial segments
    • Margin Expansion through improved efficiency despite raw material price fluctuations
    • Strong Order Book from renewable energy storage solutions & data center power backups
    • One-time gain: ₹111 Cr. insurance settlement for Chittoor plant fire damage

    Growth Strategy & Expansion Plans

    Investment in Subsidiaries

    • ₹200 Cr. in Amara Raja Circular Solutions (ARCS)
      • Expansion of Battery Recycling Plant
      • Supports sustainability & cost optimization
    • ₹50 Cr. in Amara Raja Power Systems (ARPS)
      • Strengthening operational & manufacturing capabilities

    Gigafactory & Lithium-Ion Battery Expansion

    • Development of “Amara Raja Giga Corridor” (16 GWh capacity by 2030)
    • ₹9,500 Cr. investment in Lithium-Ion cell manufacturing
    • Indigenous Lithium-Ion battery technology development for EVs & energy storage
    • R&D focus on solid-state batteries

    Lead-Acid Battery Capacity Expansion

    • Strengthening market leadership in automotive, telecom, industrial, and solar applications
    • Higher capacity utilization at existing plants

    Industry & Competitive Landscape

    Industry Outlook

    • EV Penetration in India: Expected rise from 1.2% (2023) to 20%+ by 2030
    • Stationary Energy Storage Market: 15% CAGR growth projection
    • Continued growth in Lead-Acid Battery Market
    Competitor Focus Areas Threat Level
    Exide Industries Lead-Acid, Lithium-Ion, EV Batteries High (strong R&D, market leader)
    Luminous (Schneider Electric) Home & commercial power backup Medium
    Tata AutoComp Gotion EV Batteries, Charging Solutions High (Tata’s backing)
    Reliance New Energy (RNEL) Lithium-ion cell gigafactories High (huge capital investment)

    Key Risks & Challenges

    Raw Material Price Volatility

    Lead & lithium prices fluctuate due to global supply chain issues

    Competitive Threat in Lithium-Ion Batteries

    Aggressive expansion by Reliance, Tata AutoComp, and Exide in Li-ion manufacturing

    Slow EV Adoption in India

    Despite increasing government incentives, EV penetration remains low

    Financial Projections & Valuation

    Metric FY2025E FY2026E FY2027E
    Revenue (₹ Cr.) 12,500 14,200 16,000
    EBITDA Margin 14.0% 14.5% 15.2%
    Net Profit (₹ Cr.) 1,000 1,200 1,450
    EPS (₹) 52 63 77
    ROE 14.5% 15.2% 16.1%

    Valuation Highlights

    • Target Price: ₹1,300 (P/E of 22x FY26E EPS)
    • Upside Potential: 21.6% from current levels
    • Valuation: Moderately Attractive
    • Key Metrics: Steady cash flow, strong growth pipeline & 18.7% ROCE

    Investment Thesis

    ✅ Strengths

    • Market leader in lead-acid batteries with a dominant market share
    • Strong financials with high ROCE & low debt (D/E: 0.04)
    • Massive investments in lithium-ion gigafactories & EV battery tech
    • Growing demand for energy storage solutions (renewables, UPS, data centers)

    ⚠️ Risks

    • Intense competition from Exide, Reliance, Tata AutoComp in the Li-ion segment
    • Dependency on raw material imports (lead & lithium)
    • Uncertain government policy shifts in EV subsidies

    🟢 Verdict

    • Great long-term investment for India’s energy storage & EV revolution
    • Short-term catalysts: Lithium-Ion Gigafactory, Battery Recycling, Data Center Power Solutions
    • Long-term play: EV Batteries & Renewable Energy Storage Growth 🚀

    Final Take

    Amara Raja Energy & Mobility Ltd. is a strong long-term play in India’s battery & energy storage market, with robust fundamentals, expansion into lithium-ion, and steady revenue growth. 🚀

    Disclaimer

    This report is for informational purposes only and should not be considered investment advice. Investors should conduct their own research and consult financial advisors before making investment decisions.

  • LIC Q3 FY2025: Insurance Giant Unveils Aggressive Expansion Strategy

    Life Insurance Corporation (LIC) – Q3 FY2025 Results Research Report

    Life Insurance Corporation (LIC) – Q3 FY2025 Results

    Ticker: NSE: LICI | BSE: 543526 | Date: February 7, 2025

    Value Pick Best Stock to buy

    Investment Summary

    Life Insurance Corporation of India (LIC) remains India’s largest life insurer, with a 57.42% market share in total premiums and 64.53% market share in policies. Despite increasing competition from private players, LIC continues to dominate the industry due to its massive distribution network, trusted brand, and large asset base of ₹54.77 lakh crore.

    Q3 FY2025 Results Key Highlights

    • Premium growth of +5.51% YoY (₹3,40,563 Cr vs ₹3,22,776 Cr in Q3 FY24)
    • Profit After Tax (PAT) up +8.27% YoY (₹29,138 Cr vs ₹26,913 Cr in Q3 FY24)
    • Embedded Value (IEV) surged by +24% YoY to ₹8,21,716 Cr, indicating strong intrinsic value growth
    • Solvency ratio improved to 2.02, reflecting a solid capital position

    Key Financial Metrics

    Metric Q3 FY25 Q3 FY24 YoY Change
    Total Premium Income ₹3,40,563 Cr ₹3,22,776 Cr +5.51%
    Individual New Business Premium ₹1,78,975 Cr ₹1,71,040 Cr +4.64%
    Total Group Business Premium ₹1,19,147 Cr ₹1,13,057 Cr +5.39%
    Profit After Tax (PAT) ₹29,138 Cr ₹26,913 Cr +8.27%
    Assets Under Management (AUM) ₹54,77,651 Cr ₹49,66,371 Cr +10.29%

    Strategic Growth Plans

    1. Expansion of Product Portfolio

    LIC now offers 38 insurance products, including:

    • 24 Individual Products
    • 8 Group Products
    • 5 Individual Riders & 1 Group Rider

    Increased Focus on Non-Par Products:

    • Non-par products now contribute 27.68% of APE, up from 14.04% in Q3 FY24
    • ULIP segment growth: +210.79% YoY (₹732 Cr to ₹2,275 Cr)

    Strategic Rationale: LIC’s shift towards higher-margin non-participating products is expected to improve profitability and long-term value creation.

    2. Distribution & Digital Transformation

    • Largest agency force in India with 14.19 lakh agents
    • Bancassurance & Alternate Channels New Business Premium grew +31.06% YoY to ₹2,003.95 Cr

    Tech Initiatives:

    • AI Chatbots for policy queries
    • WhatsApp-based policy servicing & digital KYC integration
    • Ananda App: 8.3% of policies now sold digitally

    Strategic Rationale: Strengthening digital sales will counter competition from private insurers like HDFC Life & ICICI Prudential.

    Competitive Landscape & Risks

    Key Competitors

    HDFC Life, ICICI Prudential, SBI Life, Max Life, Bajaj Allianz

    Risks & Challenges

    • Regulatory Risks: IRDAI changes may impact LIC’s product mix & capital allocation
    • Market Share Erosion: Private players are aggressively expanding
    • Investment Risk: Large exposure to equity markets increases volatility risk
    • Operational Risks: Persistency ratios must further improve for long-term profitability

    Valuation & Investment Thesis

    Valuation Metrics

    • Market Cap: ₹5,16,152 Cr
    • Current Price: ₹816
    • P/E Ratio: 12.0
    • Book Value: ₹154
    • Dividend Yield: 1.23%
    • ROE: 63.4%
    • Price-to-Book Ratio (P/BV): 5.3x

    Investment Thesis

    • ✅ Strong Fundamentals: High ROE (63.4%), improving persistency, and stable cash flows
    • ✅ Undervalued vs. Growth Potential: With Embedded Value growth of +24% YoY, LIC remains undervalued vs. global peers
    • ✅ Digital & Product Expansion: Rising non-par product sales & bancassurance will boost VNB margins

    Valuation Estimate: ₹950 – ₹1,050 (15-25% upside potential)

    Conclusion

    LIC remains a strong long-term investment, backed by dominant market share, high AUM, and increasing profitability. However, competition & regulatory risks remain key concerns.

    Disclaimer

    This report is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions.

  • Britannia Q3 Results: Revenue Jump, ₹500Cr Expansion, 12-15% CAGR Target

    Britannia Industries Q3 FY2025 results Analysis

    Britannia Industries Limited

    Q3 FY2025 Results Research Report

    Stock Overview

    ₹1,19,376 Cr.
    Market Cap
    ₹4,956
    Current Price
    ₹6,473 / ₹4,641
    52-Week High/Low
    54.9
    Stock P/E
    ₹133
    Book Value
    1.48%
    Dividend Yield
    48.9%
    ROCE
    57.1%
    ROE

    Q3 FY2025 Financial Performance

    ₹4,592.62 Cr.
    Revenue
    ↑ 7.9% YoY
    ₹582.3 Cr.
    Net Profit
    ↑ 4.8% YoY
    ₹826.50 Cr.
    EBITDA
    18.0% Margin
    ₹24.15
    EPS
    vs ₹23.11 YoY

    Expense Analysis

    Cost of Materials Consumed ₹2,629.90 Cr. (57.2%)
    Employee Benefits ₹105.85 Cr. (2.3%)
    Finance Costs ₹44.56 Cr. (1.0%)
    Depreciation & Amortization ₹82.38 Cr. (1.8%)
    Other Expenses ₹827.60 Cr. (18.0%)
    Total Expenses ₹3,874.65 Cr. (84.4%)

    Strategic Growth Plans

    Capacity Expansion & Capex

    ₹500-600 Cr. targeted investment towards:

    • Manufacturing automation
    • New production units in rural India
    • Dairy business expansion
    • International expansions

    Product & Brand Strategy

    • New health & wellness products
    • Premium biscuit segment expansion
    • Dairy-based product innovation
    • Premium category focus

    Digital & Rural Expansion

    • E-commerce platform integration
    • Direct distribution network
    • Rural market penetration
    • Digital sales channels

    Competitive Landscape

    Competitor Revenue (₹ Cr.) Market Share Key Strengths
    Britannia 17,580 36% Brand loyalty, strong margins, rural reach
    Parle 16,200 34% Mass-market dominance, affordability
    ITC 10,500 20% Strong advertising & premium offerings
    Nestlé 17,500 10% Diversified portfolio, dairy dominance

    Key Risks & Challenges

    Commodity Inflation

    Wheat, milk, and sugar price fluctuations may pressure margins

    Cost-push inflation could lead to pricing challenges

    Regulatory Risks

    FSSAI regulations on sugar & fat content

    Increased taxation on packaged food items

    Competition

    ITC’s aggressive marketing in premium biscuits

    Parle’s deep penetration in rural India

    Market Risks

    Currency & export risks in international markets

    Consumer demand slowdown impact

    Valuation & Investment Thesis

    54.9x
    P/E Ratio
    Premium vs. Industry Avg ~40x
    37.3x
    Price-to-Book (P/B)
    Reflects high ROE
    ~35x
    EV/EBITDA
    Premium due to margins
    1.48%
    Dividend Yield
    Stable payout policy

    Investment Rationale

    • High ROE (57.1%) & ROCE (48.9%) indicating efficient capital utilization
    • Consistent earnings growth with sales growth of 8.5% CAGR (3Y avg)
    • Resilient business model with market leadership and strong pricing power
    • Strategic expansion into dairy & bakery segments as future growth drivers
    • Defensive FMCG stock providing steady earnings across economic cycles

    Final Verdict: HOLD with Positive Bias

    Premium
    Valuation
    P/E 54.9x
    5-8%
    Short-Term Growth
    Stable margins
    12-15%
    Long-Term CAGR
    3-5 years outlook
    ₹4,500-4,700
    Accumulation Range
    Buy on dips

    Additional Performance Metrics

    5.12%
    Sales Growth (YoY)
    0.72%
    Profit Growth (YoY)
    8.48%
    Sales Growth (3Yrs)
    4.89%
    Profit Growth (3Yrs)
    50.6%
    Promoter Holding
    24.1 Cr.
    No. of Equity Shares
    ₹2,754 Cr.
    Debt
    ₹3,186 Cr.
    Reserves

    Disclaimer

    This report is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult a financial advisor before making any investment decisions.

  • Anant Raj Q3FY25 Results: 54.6% PAT Growth, ₹1000Cr Expansion Plan

    Anant Raj Limited – Q3 FY2025 Results

    Anant Raj Limited

    Value Pick Multibagger stock for long term

    Q3 FY2025 Results

    Stock Overview

    Market Cap ₹21,834 Cr
    Current Price ₹638
    52-Week High/Low ₹948 / ₹281
    Stock P/E 56.7x
    Book Value per Share ₹112

    Key Financial Metrics

    Dividend Yield 0.11%
    ROCE 8.56%
    ROE 8.05%
    Debt ₹386 Cr
    Reserves ₹3,759 Cr

    Q3 FY2025 Financial Results

    Particulars Q3 FY2025 Q3 FY2024 % Change YoY
    Revenue from Operations ₹534.64 Cr ₹392.27 Cr +36.3%
    Total Income ₹543.97 Cr ₹401.02 Cr +35.7%
    EBITDA ₹123.50 Cr ₹93.44 Cr +32.1%
    EBITDA Margin 23.1% 23.8% Stable
    Profit Before Tax (PBT) ₹131.75 Cr ₹86.30 Cr +52.7%
    Net Profit (PAT) ₹110.37 Cr ₹71.43 Cr +54.6%
    Earnings Per Share (EPS) ₹3.23 ₹2.22 +45.5%

    Key Q3 FY2025 Highlights

    • Revenue grew by 36.3% YoY, driven by strong sales in luxury residential and commercial projects
    • Net Profit surged by 54.6%, reflecting operational efficiencies
    • Debt remains low at ₹386 Cr, ensuring a strong balance sheet
    • EPS growth of 45.5%, indicating rising shareholder value

    Business & Expansion Strategy

    Residential Segment

    • Launch of new luxury residential projects in Gurugram, Noida, and Manesar
    • Targeting HNIs with premium apartments and villas
    • Strengthening presence in Delhi NCR, Bangalore, and Pune

    Commercial & IT Parks

    • Expansion of Anant Raj IT Park in Manesar
    • Development of Grade A office spaces
    • Flexible co-working infrastructure

    Hospitality & Retail

    • Entering luxury hospitality segment
    • High-end serviced apartments and hotels
    • Expansion of retail spaces

    Affordable Housing

    • New focus on affordable housing projects
    • Mid-segment housing expansion
    • Capturing India’s urbanization trends

    Capital Expenditure & Strategic Investments

    Capex Plan (FY2025-FY2027): ₹1,000 Cr+

    Land Acquisitions ₹500 Cr
    IT Park Expansion ₹300 Cr
    Infrastructure Development ₹200 Cr

    Strategic Financial Moves

    • NCD Repayment: ₹103.75 Cr in Q3 FY2025
    • Convertible Warrants: ₹99.99 Cr raised via preferential issue at ₹730/share

    Competitive Landscape & Industry Outlook

    Company Market Cap (₹ Cr.) Revenue (₹ Cr.) P/E Ratio ROE (%)
    Anant Raj Ltd ₹21,834 ₹1,962 56.7x 8.05%
    DLF Ltd ₹1,63,000 ₹7,800 62.3x 11.2%
    Godrej Properties ₹66,500 ₹4,200 55.5x 9.4%
    Prestige Estates ₹41,700 ₹7,150 38.8x 13.5%

    Industry Overview

    • Real estate demand remains strong, fueled by urbanization and infrastructure growth
    • Luxury housing segment is booming, driven by HNI and NRI investments
    • Commercial real estate demand is increasing, especially in IT hubs

    Competitive Analysis

    • Anant Raj trades at a lower P/E than DLF and Godrej Properties
    • ROE is lower than competitors but showing improvement potential
    • Revenue growth outpacing most peers

    Financial Projections (FY2025-FY2027)

    Metric FY2025E FY2026E FY2027E
    Revenue (₹ Cr) 2,150 2,700 3,200
    EBITDA Margin 24.0% 25.5% 26.0%
    Net Profit (₹ Cr) 430 525 630
    EPS (₹) 13.5 16.4 19.8
    ROE (%) 9.2% 10.8% 12.1%

    Growth Drivers

    • Expansion into luxury residential & IT parks
    • Higher rental income from commercial real estate
    • Margin improvement from premium projects

    Valuation & Investment Thesis

    Current Valuation Metrics

    Stock P/E 56.7x
    Price-to-Book (P/B) 5.7x

    Valuation Estimate (FY2026)

    Projected EPS ₹16.4
    Industry Avg. P/E ~50x
    Target Price ₹820
    Potential Upside 29%

    Investment Rationale

    Why Invest in Anant Raj Ltd?

    • High Revenue & Profit Growth – 48.5% YoY sales growth & 67.4% profit growth
    • Expanding Asset Base – IT parks, commercial & luxury housing
    • Debt Under Control – ₹386 Cr total debt, NCD repayments underway
    • Valuation Upside – Estimated price target of ₹820 (~29% upside)

    Risk Assessment

    Key Risk Factors

    • 🚨 Market Risks: Potential slowdowns in real estate demand due to macroeconomic factors
    • 🚨 Regulatory Risks: Land acquisition and RERA compliance could impact project timelines
    • 🚨 Interest Rate Risks: Rising borrowing costs could pressure profit margins

    Disclaimer: This report is not investment advice. Investors should conduct their own research before making investment decisions.

  • Dabur Q3 FY25: 19% global Growth Ayurveda Expansion

    Dabur India Limited – Q3 FY2025 Results

    Dabur India Limited -Q3 FY2025 Results

    Value Pick Best Stock for long term investment

    Market Metrics

    Market Cap: ₹95,627 Cr

    Current Price: ₹539

    52W High/Low: ₹672 / 489

    Key Ratios

    P/E: 54.1

    Book Value: ₹58.5

    Dividend Yield: 1.02%

    Returns & Growth

    ROCE: 22.3%

    ROE: 19.2%

    Sales Growth (3Yrs): 9.06%

    Financial Position

    Debt: ₹1,752 Cr

    Reserves: ₹10,185 Cr

    Promoter Holding: 66.3%

    Q3 FY2025 Performance Overview

    Metric Q3 FY25 Q3 FY24 YoY Growth
    Revenue from Operations ₹3,355 Cr ₹3,255 Cr +3.1%
    Operating Profit ₹682 Cr ₹668 Cr +2.1%
    Operating Margin 20.3% 20.5% -20 bps
    Net Profit ₹522 Cr ₹514 Cr +1.6%
    A&P Spend 6.8% 7.5% -70 bps

    Segment Performance Analysis

    Domestic Business (₹2,448 Cr, +1.4% YoY)

    Foods & Beverages (48.2% of Sales)

    • Revenue: ₹1,110 Cr
    • Growth: +30% YoY
    • Strong performance in Hommade & Badshah spices
    • Beverages segment declined 10.3% due to weak festive demand

    Healthcare (37.9% of Sales)

    • Revenue: ₹872 Cr
    • Health supplements declined 3.4%
    • Chyawanprash maintained market leadership
    • OTC & Ethical category remained flat

    Home & Personal Care (11.8% of Sales)

    • Revenue: ₹273 Cr
    • Home Care: -10.3% YoY
    • Personal Care: +2.7% YoY
    • Market share gains in Oral Care

    International Business (25% of Sales)

    • Revenue: ₹847 Cr (+18.9% CC Growth)
    • Egypt: +54.6% growth
    • Turkey: +28.2% growth
    • Bangladesh: +21.6% growth
    • MENA market: +17.5% growth

    Strategic Initiatives & Capex Plans

    Capital Expenditure

    • Expansion of Badshah spices production capacity
    • Investment in Ayurvedic product portfolio
    • Modernization of manufacturing facilities

    Branding Efforts

    • Rural activation programs
    • Festival season campaigns (Kumbh Mela, Durga Puja)
    • Celebrity endorsements and digital marketing

    Market Penetration Strategy

    • Focus on premium healthcare segments
    • Expansion of ayurvedic product range
    • Strengthening rural distribution network

    Competitive Landscape & Risks

    Key Competitors

    • Hindustan Unilever (HUL)
    • ITC Limited
    • Marico

    Risk Factors

    • Inflationary pressures on raw materials
    • Increased competitive pricing pressure
    • Unpredictable weather impacting seasonal products
    • Currency fluctuations in international markets

    Valuation & Investment Thesis

    Current Valuation Metrics

    Metric Value Industry Avg
    P/E Ratio 54.1x ~45x
    Price/Book 9.2x ~8x
    Dividend Yield 1.02% ~1.5%

    Growth Projections

    • Sales CAGR (3-5 Years): 8-10%
    • PAT CAGR (3-5 Years): 6-8%
    • Target Price (1 Year): ₹590-₹610

    Investment Recommendation

    Long-Term Buy Recommendation

    • Strong brand moat and rural resilience
    • Stable FMCG exposure with defensive characteristics
    • Premium valuation justified by market leadership
    • Robust international growth prospects

    Near-Term Considerations

    • Current P/E of 54.1x above historical averages
    • Moderate earnings growth trajectory
    • Margin pressures from input costs
    • Competitive intensity in key segments

    Growth Drivers & Future Outlook

    Key Growth Catalysts

    • Rising demand for Ayurvedic & natural products
    • Expanding rural reach and distribution
    • Premiumization in healthcare & spices categories
    • Strong international market expansion

    Digital Initiatives

    • E-commerce channel optimization
    • Direct-to-consumer (D2C) platforms
    • Digital-first product launches
    • Enhanced online customer engagement

    Financial Projections

    Metric FY2025E FY2026E
    Revenue Growth 8-10% 10-12%
    EBITDA Margin 20-21% 21-22%
    PAT Growth 6-8% 8-10%

    Management Commentary & Strategic Focus

    Key Strategic Priorities

    • Portfolio premiumization and innovation
    • Cost optimization and efficiency initiatives
    • Market share gains in core categories
    • International business expansion

    Innovation Pipeline

    • New product launches in premium Ayurvedic segment
    • Extension of Badshah spices portfolio
    • Enhanced health supplements range
    • Modern format personal care products

    Technical Analysis

    Price Trends

    • Current Price: ₹539
    • 52-Week Range: ₹489 – ₹672
    • 200-Day Moving Average: ₹545
    • Support Levels: ₹520, ₹500
    • Resistance Levels: ₹560, ₹580

    Conclusion

    Dabur India continues to demonstrate resilience in a challenging market environment, supported by its strong brand portfolio and diversified presence across categories. The company’s focus on premium segments, rural expansion, and international growth presents significant opportunities for long-term value creation.

    Key Investment Considerations

    • Strong brand equity in natural and Ayurvedic segments
    • Robust international business growth
    • Premium valuation reflecting market leadership
    • Potential for margin expansion through premiumization

    Disclaimer: This report is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. Past performance is not indicative of future returns. The information contained herein is believed to be reliable but cannot be guaranteed for completeness or accuracy.

  • Senores Pharma Q3FY25: 142% PAT Growth, ₹490Cr War Chest for Global Expansion

    Senores Pharmaceuticals Limited – Value Pick Multibagger Stock

    Senores Pharmaceuticals Limited Q3 FY2025 Results

    Value Pick Multibagger Stock for long term investment

    Company Overview

    Senores Pharmaceuticals Limited (SPL) is a research-driven pharmaceutical company specializing in generic and specialty pharmaceuticals. Operating primarily in regulated markets such as the US, Canada, and the UK, with expanding presence across Latin America, Africa, Southeast Asia, and the Middle East.

    Key Strengths

    • Strong regulatory approvals: USFDA, WHO-GMP, and DEA-compliant facilities
    • Growing footprint in regulated markets with long-term distribution agreements
    • Diverse revenue streams: Branded generics, APIs, and contract manufacturing
    • High-margin complex generics with CGT exclusivity
    • Backward integration into API manufacturing

    Financial Performance – Q3 FY2025

    Metric Q3 FY25 YoY Growth 9M FY25 YoY Growth
    Total Income ₹106.4 Cr +35.2% ₹288.1 Cr +157%
    Gross Profit ₹65.7 Cr +116.2% ₹164.9 Cr +221.1%
    EBITDA ₹29.1 Cr +91.8% ₹74.3 Cr +287%
    PAT ₹17.2 Cr +142.3% ₹40.7 Cr +162%

    Business Segment Performance

    Segment Q3 FY25 Revenue YoY Growth 9M FY25 Revenue YoY Growth
    Regulated Markets ₹70.2 Cr +2.5% ₹180.5 Cr +99.8%
    Emerging Markets ₹26.1 Cr +289.3% ₹84.6 Cr +1,164.8%
    Others (API & Injectables) ₹6.8 Cr +90.6% ₹18.9 Cr +25.6%

    Growth Plans & Expansion Strategy

    Market Expansion

    • Entering Brazil, Australia, and New Zealand markets
    • 537 pending product registrations in Southeast Asia, Africa, and Latin America

    Manufacturing & R&D

    • USFDA-approved sterile injectables facility in Atlanta
    • API manufacturing capacity increase: 25 MTPA to 169 MTPA
    • R&D focus on complex generics and critical care products

    CDMO & CMO Partnerships

    • Strategic alliances with pharmaceutical giants
    • Strong growth expected in CDMO market

    Products & Pipeline

    Category Count
    Commercialized Products (Regulated) 22
    CDMO/CMO Commercial Products 21
    Approved ANDAs (US Market) 24
    Pipeline CGT Generics 28
    Pipeline Products 51
    CDMO/CMO Pipeline Products 69
    Approved Products (Emerging Markets) 237
    Products Under Registration 537

    Capital Expenditure & IPO Fund Utilization

    Use of Funds Planned (₹ Cr) Utilized (₹ Cr) Unutilized (₹ Cr)
    Atlanta Injectables Facility 107 0 107
    Debt Repayment 73.5 0 73.5
    Subsidiary Loan Repayment 20.2 0 20.2
    Working Capital 102.8 0 102.8
    Strategic Acquisitions 154.4 0 154.4
    General Corporate & Offer Expenses 42.2 10 32.2
    Total 500.0 10.0 490.0

    Competitive Landscape & Risks

    Competitive Edge

    • Second-highest CGT Exclusivity among industry peers
    • Regulated market compliance (USFDA, DEA, WHO-GMP)
    • Backward integration into APIs, reducing costs

    Key Risks

    • High P/E Ratio (80.4) compared to industry peers
    • Competition from global pharma giants
    • Regulatory risks: Stricter USFDA scrutiny
    • Execution risk in scaling CDMO partnerships

    Valuation Metrics

    Market Cap

    ₹2,532 Cr

    Current Price

    ₹550

    Stock P/E

    80.4

    ROCE

    11.5%

    ROE

    25.2%

    Debt

    ₹258 Cr

    Reserves

    ₹174 Cr

    Dividend Yield

    0.00%

    Sales Growth (YoY)

    507%

    Profit Growth (YoY)

    273%

    Investment Thesis

    • High revenue growth (157% YoY) with expanding profit margins
    • Diversified portfolio spanning regulated and emerging markets
    • Upcoming capacity expansions will drive long-term scalability
    • CDMO partnerships provide stable revenue, reducing volatility
    • Valuation concerns due to high P/E (80.4), but growth potential is strong

    Conclusion

    Senores Pharmaceuticals is a high-growth pharma stock, expanding aggressively in regulated markets, CDMO, and APIs. However, high valuations and execution risks warrant cautious optimism.

    Disclaimer

    This report is for informational purposes only and not investment advice. Investors should conduct independent research before making financial decisions.

  • Tata Elxsi Q3 FY25: AI-Driven Growth Amid Global Tech Transformation | Investment Research

    Tata Elxsi Ltd. – Value Pick : Best share to buy Q3 FY25

    Tata Elxsi Ltd.

    Value Pick: Best share to buy today (Q3 FY25)

    Company Overview

    Tata Elxsi, a subsidiary of the Tata Group, is a global leader in design and technology services across critical industries such as Transportation, Media, Communications, and Healthcare. The company leverages advanced technologies like AI, IoT, and cloud computing to deliver innovative solutions. Despite a challenging macroeconomic environment, Tata Elxsi has maintained a stable operational performance.

    Key Insights from Investor Presentation

    Financial Performance

    Revenue

    ₹939.2 Cr. (+2.7% YoY, -1.7% QoQ)

    PAT

    ₹199 Cr. (-3.6% YoY)

    EBITDA Margin

    26.3% (-7.4% QoQ)

    Cash Position

    Reserves

    ₹2,424 Cr.

    Debt

    ₹206 Cr.

    Growth Drivers

    Sectoral Strengths

    • Healthcare & Lifesciences: Grew 1.1% QoQ, driven by regulatory services and Gen AI-powered digital engineering
    • Transportation: Growth of 0.5% QoQ, focusing on ADAS Level 3 development
    • Media & Communications: Marginal growth of 0.4% QoQ

    Geographic Diversification

    • India: 21.9% YoY growth
    • Japan and emerging markets: 66.8% YoY growth

    Product Innovation

    • Launch of AVENIR SDV Suite at CES 2025
    • Collaboration with Suzuki through Pune ODC
    • Expansion of digital twin capabilities

    Competitive Landscape

    Tata Elxsi faces competition from global IT players and niche engineering design firms. Key risks include:

    • Dependency on top 10 clients (44.8% of revenue)
    • Geopolitical instability in key markets
    • Currency fluctuations in export-heavy segments

    Investment Thesis

    Current Price

    ₹6,001

    P/E Ratio

    46.2x

    ROE

    34.5%

    Key Catalysts

    • Positive momentum in healthcare and emerging markets
    • Margin improvement opportunities
    • Long-term strategic deals ramping up

    Valuation Estimate

    Target price range: ₹6,800-₹7,200 (12-month horizon)

    Recommendation: Accumulate

    Investors can capitalize on near-term weakness to build a position in Tata Elxsi, leveraging its leadership in high-growth segments like ADAS, green mobility, and AI solutions.

    Disclaimer: This report is for informational purposes only and does not constitute investment advice. The analysis relies on publicly available data and may not account for all variables. Past performance does not guarantee future results. Consult your financial advisor for tailored advice.

  • IndiaMART Q2 FY25 Analysis: Stable 18% Revenue Growth | B2B Leader’s

    IndiaMART -Value Picks : Long-Term Multibagger Stocks: Investing in High potential stocks before value realisation

    IndiaMART InterMESH Limited

    Value Pick : Best Share buy today

    Executive Summary

    IndiaMART InterMESH Limited is a leading B2B marketplace in India. The company’s Q2 FY2025 results highlight modest revenue growth but challenges in collections growth due to customer churn, particularly in the silver category. Strategic initiatives are being taken to address these concerns. The competitive landscape remains dynamic, with IndiaMART focusing on maintaining its leadership position while navigating structural challenges in customer acquisition and retention.

    Key Metrics

    Market Cap
    ₹13,941 Cr
    Current Price
    ₹2,322
    Stock P/E
    32.4
    Dividend Yield
    0.86%
    ROCE
    23.9%
    ROE
    17.6%
    Sales Growth (3Y)
    21.4%
    Profit Growth (3Y)
    33.6%

    Financial Performance

    Q2 FY2025 Highlights:

    • Revenue: ₹348 Cr (YoY growth of 18%)
    • Collections: ₹356 Cr (YoY growth of 6%)
    • EBITDA Margin: 36%
    • Net Profit: ₹135 Cr (Consolidated)
    • Deferred Revenue: ₹1,483 Cr (+19% YoY)
    • Paying Suppliers: 218,000

    Future Growth Drivers

    Product Refinement

    Enhanced matchmaking algorithms and improved user engagement through measures like reducing supplier competition per inquiry (4 suppliers per buyer vs. 6 earlier).

    Technology Integration

    Initiatives such as leveraging WhatsApp for inquiries and implementing Real-Time Customer Solutions (RCS) have started contributing positively to unique business inquiries.

    Strategic Investments

    Focus on software-as-a-service (SaaS) offerings such as Busy Infotech and Livekeeping for SME clients. These tools are being integrated into IndiaMART’s platform to enhance value delivery.

    Capital Expenditure and Strategic Rationale

    Recent investments exceeding ₹600 Cr in strategic acquisitions and software integrations aim to diversify revenue streams and enhance platform stickiness for SME users. SaaS initiatives like Vyapar and Livekeeping are expected to generate synergies with IndiaMART’s core business.

    Competitive Landscape

    • Primary Competitors: Justdial, TradeIndia, and global giants like Amazon B2B
    • Key Advantage: First-mover advantage, strong cash reserves, and platform breadth
    • Challenges: Elevated competition from Justdial post-COVID and emergence of niche platforms

    Risks

    • Customer Churn: Persistent churn in the silver category could impact future revenue growth
    • Collection Growth: Slowing collection growth (5% YoY) may signal structural issues
    • Economic Environment: B2B market performance is tied closely to broader economic conditions
    • Competition: Aggressive customer acquisition by competitors could erode market share

    Valuation Estimate

    Using a P/E multiple of 30x (considering the industry average), the valuation per share based on an estimated FY2025 EPS of ₹75 is approximately ₹2,250. This aligns closely with the current market price, indicating a fairly valued stock with potential upside contingent on improved execution.

    Investment Thesis

    IndiaMART’s strong market position, robust financial health, and focus on strategic investments position it for sustained long-term growth. However, near-term challenges, particularly around customer churn and collection growth, warrant caution. Investors should monitor progress on operational improvements and management’s ability to execute its strategic initiatives.

    Conclusion

    Recommendation: Hold

    IndiaMART is a resilient market leader with promising growth initiatives. However, resolving churn issues and achieving double-digit collection growth are critical for re-rating.

    Disclaimer: This report is for informational purposes only and does not constitute financial advice. Investors should perform their own due diligence and consult financial advisors before making investment decisions.

    • Value Picks fin.ctoi.in
    Value Picks fin.ctoi.in
    Value Picks

    Dont Miss our Value picks

    SUBSCRIBE TO OUR NEWSLETTER to Get short term, long term and multi-bagger

    We don’t spam! Read our privacy policy for more info.